Related Experiment Video
Updated: Jan 18, 2026

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
Structural Elucidation and Covalent Modulation of the Autorepressed Orphan Nuclear Receptor NR2F6
Guido J M Oerlemans1, Maxime C M van den Oetelaar1, Siebe P van den Elzen1
1Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute of Complex Molecular Systems, Technische Universiteit Eindhoven, 5612 AZ Eindhoven, The Netherlands.
Abstract:
The orphan nuclear receptor NR2F6 (Nuclear Receptor subfamily 2 group F member 6) is an emerging therapeutic target for cancer immunotherapy. Upregulation of NR2F6 expression in tumor cells has been linked to proliferation and metastasis, while in immune cells NR2F6 inhibits antitumor T-cell responses. Small molecule modulation of NR2F6 activity might therefore be a novel strategy in cancer treatment, benefiting from this dual role of NR2F6. However, there are no molecular strategies available for targeting NR2F6, hampered among others by lack of structural insights and appropriate biochemical assays. To overcome these challenges, several noncanonical nuclear receptor coregulator peptide motifs were identified to be constitutively recruited to the NR2F6 ligand binding domain (LBD). Co-crystallization of the NR2F6 LBD with a peptide from the coregulator Nuclear Receptor Binding SET Domain Protein 1 (NSD1) enabled, for the first time, the structural elucidation of the unliganded (apo) form of NR2F6. This revealed an autorepressed, homodimeric LBD conformation in which helix 12 folds over the canonical coregulator binding site, generating an alternative contact surface for NSD1 binding. Screening of a focused library of covalent NR probes identified compounds that preferentially target a cysteine residue near the NSD1 binding site, inhibiting NR2F6 coregulator recruitment. Combined, these results provide structural insights into the ligand-independent transcriptional activity of NR2F6 and may serve as a starting point for the development of novel NR2F6 modulators.
Insights
Nuclear Receptor NR2F6 is a cancer immunotherapy target. Researchers elucidated its structure, revealing an autorepressed conformation and identifying covalent probes that inhibit coregulator recruitment, paving the way for novel cancer therapeutics.
Area of Science:
- Molecular biology
- Structural biology
- Cancer research
Background:
- The orphan nuclear receptor NR2F6 is a key target in cancer immunotherapy due to its roles in tumor growth and immune suppression.
- Targeting NR2F6 offers a novel strategy for cancer treatment, but lacks molecular tools and structural data.
- Understanding NR2F6's structure is crucial for developing effective modulators.
Purpose of the Study:
- To elucidate the structure of the unliganded NR2F6 ligand binding domain (LBD).
- To identify molecular strategies for targeting NR2F6 activity.
- To provide a basis for developing novel NR2F6 modulators for cancer therapy.
Main Methods:
- Co-crystallization of the NR2F6 LBD with a peptide from the Nuclear Receptor Binding SET Domain Protein 1 (NSD1).
- Structural elucidation of the unliganded NR2F6 LBD using X-ray crystallography.
- Screening of covalent NR probes to identify NR2F6 inhibitors.
Main Results:
- The crystal structure revealed an autorepressed, homodimeric conformation of the NR2F6 LBD with helix 12 blocking the canonical coregulator binding site.
- An alternative binding surface for NSD1 was identified in the apo-NR2F6 structure.
- Covalent NR probes targeting a specific cysteine residue were found to inhibit NR2F6 coregulator recruitment.
Conclusions:
- The study provides the first structural insights into the ligand-independent activity of NR2F6.
- The identified NR2F6 structure and binding interactions can guide the development of new cancer drugs.
- These findings represent a significant step towards creating novel NR2F6 modulators for cancer immunotherapy.
More Related Videos
12:30Production of Nurr-1 Specific Polyclonal Antibodies Free of Cross-reactivity Against Its Close Homologs, Nor1 and Nur77
Published on: August 17, 2015
09:07Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
Published on: December 19, 2018
Related Concept Videos
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Co-activators and Co-repressors
Co-activators and Co-repressors
Regulation of Nuclear Protein Sorting
RNA Polymerase II Accessory Proteins
Cooperative Binding of Transcription Regulators